ALNYLAM PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ALNYLAM PHARMACEUTICALS INC. - More news...
ALNYLAM PHARMACEUTICALS INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
- Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
- Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
- Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
- Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
- Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
- Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
- Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
- Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
- Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
- Alnylam Issues 2022 Corporate Responsibility Report
- Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
- Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
- Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
- Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
- Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
- Alnylam Announces Appointment of Peter Kellogg to Board of Directors
- Alnylam to Webcast Presentations at Upcoming March Investor Conferences
- Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
- Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
- Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
- Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
- Alnylam Announces Updates to its Board of Directors
- Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
- Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
- Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day